Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans

INTRODUCTION: Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT(1A) receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotaront an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Luan, Tsukada, Hironobu, Milanovic, Snezana, Shi, Lei, Li, Yan, Mao, Yongcai, Koblan, Kenneth S., Galluppi, Gerald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195965/
https://www.ncbi.nlm.nih.gov/pubmed/36932300
http://dx.doi.org/10.1007/s40120-023-00459-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195965/
https://www.ncbi.nlm.nih.gov/pubmed/36932300
http://dx.doi.org/10.1007/s40120-023-00459-8

Ejemplares similares